Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Palantir stock rises on UBS coverage, army deal

admin by admin
December 19, 2024
in Stock
0
Palantir stock rises on UBS coverage, army deal
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

Investing.com — Palantir Technologies Inc . (NASDAQ:PLTR) stock climbed 3% following a new coverage initiation by UBS and news of an extended partnership with the U.S. Army. The rebound comes after a 3.9% decline on Wednesday, which was influenced by the market’s reaction to hawkish comments from the Federal Reserve.

UBS analyst Karl Keirstead initiated coverage on Palantir with a Neutral rating and an $80 price target, citing a very positive outlook on the company’s fundamentals and revenue growth projections for 2025/2026 that surpass Street consensus by 200 basis points. Keirstead’s assessment is based on conversations with 17 large Palantir customers, aiming to demystify the core functions of Palantir’s offerings and their potential uplift from AI-Data exposure. Despite the positive forecast, Keirstead noted that the company’s current valuation was a factor in the neutral stance, with Palantir trading at 49 times revenue and 124 times free cash flow based on 2025 estimates, which he found challenging to justify.

In a separate development, Palantir announced an extension of its long-standing partnership with the U.S. Army. The agreement, valued at approximately $400.7 million for up to four years, with a ceiling of $618.9 million, supports the “Army Data Platform” (ADP) through the Army Vantage capability. This deal underscores Palantir’s continuing role in providing data analytics solutions to the military sector and may contribute to investor confidence in the company’s ability to secure substantial government contracts.

The UBS analyst was quoted saying, “2025/2026 estimates that are well above the Street consensus (+200bps on revs growth) and a very positive view of the fundamentals.” This commentary reflects a belief in Palantir’s strong future revenue growth and fundamental business strengths, even as the valuation remains a point of caution for the analyst.

Investors appear to have responded favorably to the combination of UBS’s coverage and the significant army contract, resulting in today’s uplift in Palantir’s stock price. As the company continues to navigate its position in the competitive data analytics market, these developments could be critical in shaping its financial trajectory and market valuation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com

Previous Post

Factbox-European companies cut jobs as economy sputters

Next Post

Roche’s Parkinson’s drug misses main goal in mid-stage trial

admin

admin

Next Post
Roche’s Parkinson’s drug misses main goal in mid-stage trial

Roche’s Parkinson’s drug misses main goal in mid-stage trial

Trending News

American Airlines grounds all US flights over technical issue

American Airlines grounds all US flights over technical issue

December 24, 2024
Column-Navigating the brave new world of bond investing – Taosha Wang

Column-Navigating the brave new world of bond investing – Taosha Wang

January 13, 2025
US stock index futures climb as the Federal Reserve meeting starts

US stock index futures climb as the Federal Reserve meeting starts

September 17, 2024
Subscribe to Insightful Word


    Recent News

    Estee Lauder stock price analysis: rebound can’t be ruled out

    Estee Lauder stock price analysis: rebound can’t be ruled out

    May 16, 2025
    Asian markets close: Nikkei flat as Japan’s GDP contracts; Sensex dips 200 pts

    Asian markets close: Nikkei flat as Japan’s GDP contracts; Sensex dips 200 pts

    May 16, 2025
    Rich List 2025: UK billionaires decline for first time in years amid market turmoil

    Rich List 2025: UK billionaires decline for first time in years amid market turmoil

    May 16, 2025
    Novo Nordisk CEO to step down as obesity drug competition intensifies

    Novo Nordisk CEO to step down as obesity drug competition intensifies

    May 16, 2025

    Recent News

    Estee Lauder stock price analysis: rebound can’t be ruled out

    Estee Lauder stock price analysis: rebound can’t be ruled out

    May 16, 2025
    Asian markets close: Nikkei flat as Japan’s GDP contracts; Sensex dips 200 pts

    Asian markets close: Nikkei flat as Japan’s GDP contracts; Sensex dips 200 pts

    May 16, 2025

    Latest News

    • Estee Lauder stock price analysis: rebound can’t be ruled out
    • Asian markets close: Nikkei flat as Japan’s GDP contracts; Sensex dips 200 pts
    • Rich List 2025: UK billionaires decline for first time in years amid market turmoil

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.